
==== Front
BMB RepBMB RepksbmbBMB Reports1976-66961976-670XKorean Society for Biochemistry and Molecular Biology 23186997BMB-45-59510.5483/BMBRep.2012.45.11.210Review ArticleCharacterization and function of human Ly-6/uPAR molecules Kong Hyun Kyung Park Jong Hoon *Department of Biological Science, Sookmyung Women’s University, Seoul 140-742, Korea* Corresponding author. Tel: +82-2-710-9414; Fax: +82-2-2077-7322; E-mail: parkjh@sookmyung.ac.kr11 2012 45 11 595 603 12 10 2012 Copyright © 2012, Korean Society for Biochemistry and Molecular Biology2012This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Human Ly-6/uPAR molecules are a superfamily composed of two subfamilies; one is the membrane bound proteins with a GPI-anchor and the other are secreted proteins without the GPI-anchor. Ly-6/uPAR molecules have remarkable amino acid homology through a distinctive 8-10 cysteine-rich domain that is associated predominantly with O-linked glycans. These molecules are encoded by multiple tightly linked genes located on Chr. 8q23, and have a conserved genomic organization. Ly-6/uPAR molecules have an interesting expression pattern during hematopoiesis and on specific tumors indicating that Ly-6/uPAR molecules are associated with development of the immune system and carcinogenesis. Thus, Ly-6/uPAR molecules are useful antigens for diagnostic and therapeutic targets. This review summarizes our understanding of human Ly-6/uPAR molecules with regard to molecular structure as well as what is known about their function in normal and malignant tissues and suggest Ly-6/uPAR molecules as target antigens for cancer immunotherapy. [BMB Reports 2012; 45(11): 595-603]

Cancer metastasisCancer therapyGene familyHematopoiesisImmune systemTumorigenesis
==== Body
INTRODUCTION
Ly-6 molecules were initially identified in mice as lymphocyte differentiation antigens (1). Ly-6 molecules are encoded by multiple tightly linked genes located on mouse chromosome 15 and have conserved genomic organization (2). Murine Ly-6 molecules are a set of structurally related and distinct collection of low molecular weight GPI-anchored cell surface glycoproteins such as Ly6a (Sca-1), Ly6b, Ly6c1, Ly6d (Thb), Ly6e (Sca-2), Ly6f, Ly6g, Ly6h, Ly6i, Ly6k, and TSA-1 antigens and are characterized by leukocyte expression (3). Secreted Ly-6 molecules without a GPI-anchoring sequence have been identified in mouse seminal vesicles (4). Murine Ly-6 molecules are expressed on fully differentiated cells in specific compartments of peripheral lymphoid tissues including the spleen, lymph nodes, and peripheral blood but limited expression occurs on non-lymphoid tissues (5). The binding of an anti-Ly-6 monoclonal antibody triggers cellular activation associated with T-cell activation, lymphoblast transformation, and signal transduction through the TcR-CD3 complex (3, 5).

The CD59 human Ly-6/uPAR molecule was first identified in human lymphoid cells (6). Since 1989, several human Ly-6/uPAR family members exhibiting varying degrees of similarity to murine Ly-6 molecules have been identified. To date, a total 20 human Ly-6/uPAR proteins, ranging from 11 to 36 kDa, have been identified and classified into transmembrane protein and secretory protein subfamilies according to the GPIanchored signaling sequence. We review the structure and function of human Ly-6/uPAR molecules in detail as well as their clinical value as biomarkers and molecular targets for cancer therapy.

CHARACTERIZATION OF HUMAN Ly-6/uPAR MOLECULES
A cluster of genes has been mapped to human chromosome 8 for many members of the human Ly-6/uPAR superfamily, particularly 8q24.3, which is synthenic to the murine Ly6 locus, the E band on mouse chromosome 15 (2). Other genes encoding the human Ly-6/uPAR superfamily members are localized on human chromosome 19q13 (uPAR, LYPD5, SAMP14, and LYPD3), chromosome 2q21-23 (LYPD1, LYPD6, and LYPD7), chromosome 11 (CD59 and SP-10), and chromosome 7 (CD177).

The Ly-6/uPAR superfamily of molecules is a single chain that has one or more LU domains. Ly-6/uPAR molecules have two distinct regions including: (i) a -NH2 terminal polypeptide, which contains a consensus leader sequence, Leu(Val/Ala) LeuLeuLeu(Ala/Val) Leu(Ala/Val) within a signal peptide 11-30 amino acids long that are destined towards the secretory pathway; and (ii) a peptide that forms a conserved 8-10 cysteine residue, hydrophilic LU domain. Ly-6/uPAR can be classified into two subfamilies based on the theoretical absence or presence of the GPI-anchor domain: one represents transmembrane proteins and the other represents secretory proteins without a GPI anchor. The transmembrane proteins of the Ly-6/uPAR superfamily have a-COOH terminal polypeptide that contains a consensus signal sequence located within 8–10 amino acids of the −NH2 terminal of a hydrophobic domain, which is required for cleavage of the -COOH peptide during phosphatidyl inositol anchor biosynthesis.

Cell surface expression of CD59, GHPIHBP1, GML, LY-6D, LY-6E, LY-6H, LY-6K, LYPD1, LYPD2, LYPD5, and PSCA and the secretion of SLURP1, SLURP2, SAMP14, and SP-10 is characterized by a single LU domain containing cysteine residues that have remarkable conservation within the mature peptide (Fig. 1). Internal disulfide bonds form between the sulfur atoms of two cysteine residues within the LU domain. In contrast to other cell surface proteins, CD177 and LYPD3 and uPAR contain two and three contiguous copies of the LU domain, respectively. LYPD6 and LYPD7 (also known as LYPD6B) have a LU domain but it contains 12 cysteine residues within the mature peptide. Cysteine residues are numbered in the context of the amino acid sequence of the Ly-6/uPAR superfamily molecules; equal spacing is observed between Cys3 and Cys6, Cys25 and Cys37, and Cys96 and Cys102 in CD59, GML, LY-6D, LY-6E, LY-6H, LY-6K, LYPD2, LYPD5, PSCA, SLURP1, SLURP2, LYPD3.1, uPAR(1-3), LYPD6, and LYPD7 amino acid sequences, although the GHPIHBP1, LYPD1, LYPD3.2 and SAMP14 sequences have different cysteine spacing between Cys25 and Cys37. Heterogeneity in cysteine residue spacing, which is observed between Cys6 and Cys15, Cys15 and Cys25, Cys37 and Cys62, Cys62 and Cys68, Cys68 and Cys96 in Ly-6/uPAR superfamily molecules, may impart specific structural epitopes.

Fig. 1. Amino acid sequence analysis of human Ly-6/uPAR molecules. The amino acid sequences of human Ly-6/uPAR superfamilies, from Leu1 to Asn103, were aligned with other sequences for comparison. Conserved cysteine residues are represented * and the boxes show amino acid identity.
Other obvious amino acid identity and homology regions have been observed (Fig. 1). Many Ly-6 family genes have a highly conserved sequence located at the -NH2 terminus; a LeuXxxCysXxxXxxCys motif at the -COOH terminus; a CysCysXxxXxxXxxXxxCys Asn motif is found in almost Ly-6/uPAR related amino acid sequence except for SP-10, which has a CysCysXxxXxxXxxXxxXxxCysAsn motif, whereas CD177 does not.

A three-dimensional crystal and solution structure of α-bungarotoxin was the first murine Ly-6/uPAR family structural model, and the amino acid sequence of the predicted β-sheet is shared between snake toxins and murine Ly-6 (7). The structural confirmation of α-bungarotoxin is maintained by internal disulfide bonds between the first and fifth, second and third, fourth and sixth, seventh and eighth, and ninth and tenth cysteine residues. Similarly, Ly-6/uPAR molecule structure can be predicted. The evolutionary relationship among the Ly-6/uPAR protein family was clarified by constructing a phylogenetic tree and Ly-6/uPAR superfamily amino acid sequences from Leu1 to Asn103 (Fig. 2). This analysis showed early divergence of the GML amino acid sequence, and a progenitor sequence of the other formed a common ancestral sequence.

FUNCTIONAL ANALYSIS OF Ly-6/uPAR MOLECULES
CD59
The plasma membrane glycoprotein CD59 (protectin) was the first member of Ly-6/uPAR sueprfamily found in humans (6). Complement regulatory protein CD59 functions as a major protective element against C5b-9, thereby blocking assembly of the membrane attack complex for human complementmediated cell lysis (8,9). Second, CD59 induces T lymphocyte activation and participates in regulating the immune response (10). Third, CD59 acts as a CD2 complex ligand and activates T cells by secreting the cytokines interleukin (IL)-1 alpha, IL-6, and granulocyte-macrophage colony-stimulating factor (11). Fourth, CD 59 functions as a regulator of tumor cell growth and apoptosis; overexpressed CD59 induces proliferation and reduces anti-apoptotic Bcl-2 expression in MCF7 cells (12). These results suggest that CD59 may be a promising target for cancer immunotherapy.

Fig. 2. Phylogenetic tree of the human Ly-6/uPAR superfamily of molecules constructed based on the amino acid sequence distance method for Ly-6/uPAR superfamilies from Leu1 to Asn103, using the neighbor-joining algorithm (99) and the WAG alpha substitution model (100). Scale bar indicates branch length.
CD177
CD177 (human neutrophil antigen-2a, NB1 glycoprotein, or polycythemia rubra vera 1) is a hematopoietic cell surface marker that is exclusively expressed on neutrophils (13). CD177 regulates neutrophil migration by binding with CD31 (platelet endothelial cell adhesion molecule-1) as a heterophilic binding partner of CD177 and induces the cytokine signaling cascade including thrombopoietin and IL-3-induced proliferation, and proteinase 3 expression, which is target antigen of anti-neutrophil cytoplasm auto-antibodies (14-16). These data indicate that regulating CD177 expression may be a novel strategy for cancer therapy by regulating the immune response.

GPIHBP1
GPIHBP1 is expressed exclusively in capillary endothelial cells along the capillary lumen and is highly expressed in heart and brown adipose tissue, which are crucial for processing of triglyceride-rich lipoproteins (17,18). These GPIHBP1 expression patterns suggest that GPIHBP1 serves as a lipoprotein lipase binding site within capillaries and may play a particularly important role in lipoprotein metabolism.

LY-6 molecules
LY-6D (E48 antigen) is expressed exclusively on normal squamous epithelia and transitional epithelium and their malignant counterparts (19). LY-6D is an effective target antigen for diagnosis and therapeutic exploitation in the management of patients with head and neck squamous cell carcinoma (HNSCC) and micrometastases to lymph nodes from HNSCC (20,21).

LY-6E (RIG-E, stem cell antigen 2, and thymic shared antigen) are expressed in squamous cells, peripheral blood, and bone marrow cells. LY-6E plays an important role in T-cell differentiation, activation of the T-cell receptor signaling pathway, and proliferation and differentiation of T2ECs (transforming growth factor [TGF]-α and TGF-β induced erythrocytic cells) that self-renew primary avian erythroid progenitors (22-24). Interestingly, LY-6E is highly expressed in various human cancers, such as colon cancer and malignant kidney cancer (25). Thus, LY-6E affects tumorigenesis by changing cell proliferation and differentiation.

LY-6H is highly expressed in the human brain, such as the cerebral cortex and also in acute lymphoblastic leukemia cells; thus, LY-6H might play an important role in both the central nervous (CNS) and immune systems (26).

LY-6K, as a cancer-testis antigen, was initially identified as a HNSCC diagnostic and therapeutic target antigen similar to LY-6D (27). Elevated LY-6K is a serologic diagnostic biomarker and therapeutic target for breast cancer, lung and esophageal carcinomas, bladder cancer, and esophageal squamous cell carcinoma (ESCC) (28-31). Induced LY-6K regulates cell growth, invasion, and migration of lung, esophageal, breast, and bladder cancer cell lines (29,30,32). Additionally, LY-6K is an immunotherapeutic target of cancer vaccine therapies because LY-6K stimulates cytotoxic T lymphocytes that have specific cytotoxic activity against ESCC cells that endogenously express LY-6K (33). Taken together, these results suggest that inhibiting LY-6K expression may be a promising target for control of these cancers and that targeting LY-6K may be a novel cancer therapy strategy.

LYPD molecules
LYPD1 (putative tumor suppressor) acts as a putative tumor suppressor in the Hela cell p53-independent pathway (34). The LYPD1 gene is highly expressed throughout the CNS, such as the cerebellum, cortex, pons, hippocampus, hypothalamus, striatum, amygdale, and septum based on quantitative reverse transcription-polymerase chain reaction and in situ hybridization analyses (35). Therefore, LYPD1 may play important roles in both tumorigenesis and the CNS.

LYPD3, also known as metastasis-associated membrane protein C4.4A, has been observed in placental tissue, skin, esophagus, and peripheral blood leukocytes (36). Human LYPD3, a uPAR structural homologue, has been detected in cancer cell lines, including melanoma, breast, bladder, and renal cell carcinoma, as well as in tumor tissue samples from malignant melanoma, metastatic breast cancer, tumor budding, and the epithelial-mesenchymal transition of colorectal cancer, non-small cell lung carcinoma with a poor prognosis, invasion and metastasis of esophageal squamous cell carcinoma, and urothelial tumors (37-42). Wound healing and metastasis promoted by LYPD3 is associated with α(6)β(4) integrin and MT1-MMP1 (43). These findings indicate that LYPD3 may also be a cancer therapy target.

LYPD6 is ubiquitously expressed in human tissues but highly expressed in brain and heart and localized in the cytoplasm where it suppresses activator protein-1 (AP-1)-mediated transcriptional activation (44).

LYPD7 is also known as LYPD6B and is highly expressed in testis, lung, stomach, and prostate, localized in the cytoplasm and activates AP-1 and phorbol myristate actetate-mediated transcriptional activation (45). Further studies are needed to gain a better understanding of the role of LYPD under normal conditions and diseases.

PSCA
Previous studies have reported that PSCA expression is upregulated in prostate cancer, pancreatic adenocarcinoma, transitional cell carcinoma, clear cell renal cell carcinoma, diffuse-type gastric cancer, endometrial adenocarcinoma, non small cell lung cancer, cervical squamous cell carcinoma, invasive micropapillary carcinoma, and glioma (46-55). In contrast, PSCA is downregulated in esophageal, gastric, stomach tumors, HNSCC, and gallbladder carcinogenesis (27,56,57). PSCA genetic variations affect susceptibility to diffuse-type gastric cancer, urinary bladder cancer, stomach cancer, and breast cancer (50,58-60). Additionally, PSCA regulates cell growth through the p53-related or immune signaling pathways, adhesion of epithelial cells, and tumor migration and metastasis (61-64). Therefore, PSCA expression may be a diagnostic marker and therapeutic target antigen for cancer therapy.

SAMP14
SAMP14 is localized near the uPAR shows testis-specific expression through the outer and inner acrosomal membranes as well as the acrosomal matrix. Antibodies against SAMP14 inhibit binding and fusion of human sperm to zona-free eggs (65). These results suggest that SAMP14 may regulate the sperm-egg interaction. However, further studies are needed to gain a better understanding of the role of SAMP14.

SLURP1 and SLURP-2
SLURP1 was the first secreted mammalian member of the Ly-6/uPAR protein superfamily identified without a GPI-anchoring signal sequence (66). SLURP1 and SLUPR2 have been identified in Mal de Meleda and hyperproliferative skin of patients with psoriasis vulgaris, respectively (67,68). SLURP1 regulates epidermal homeostasis, inflammation, keratinization, and programmed cell death as well as tumorigenesis of the colon, survival of fibroblasts, and T cell activation (69-72). SLURP2 plays a role not only in kerationcyte hyperproliferation and T cell differentiation/activation but is also competes with SLURP1 for the human nicotinic acetylcholine receptor (hAChR), thereby delaying keratinocyte differentiation and preventing apoptosis (68,73). Both SLURP1 and SLURP2 are efficient autocrine and paracrine ligands of keratinocyte nAChRs and activating the nAChR-mediated signaling pathways prevents malignant transformation of oral cells by regulating lymphocyte function and the immune system (74). Taken together, these results suggest that SLURP1 and SLURP2 may also be a target for cancer therapy by regulating the immune system and tumorigenesis.

SP-10
SP-10 is also known as acrosomal protein SP-10 or acrosomal vesicle protein 1 and has been identified as a potential contraceptive immunogen with germ cell specificity because a monoclonal antibody specific to SP-10 inhibits sperm penetration (75). SP-10, like the SAMP14 testis-specific acrosomal protein, is a spermatid differentiation marker localized to the developing acrosome of round and elongating spermatids and is associated with the inner and outer acrosomal membranes of most mature spermatids (76,77).

uPAR
uPAR was first identified in human blood monocytes and the histolytic lymphoma cell line U937 (78). uPAR plays an important role regulating degradation of extracellular matrix proteins and intravascular fibrinolysis on the cell surface (79). uPAR expression is overexpressed in various cancers, including colon cancer, invasive breast, melanocytic tumor progression, invasive brain tumor, squamous cell lung carcinoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, ovarian cancer, HNSCC, oral cancer, aggressiveness lingual squamous cell carcinoma, and ductal pancreatic carcinoma (80-92). uPAR influences cellular behavior during proliferation, inflammation, wound healing repair, adhesion, angiogenesis, and metastasis by forming a complex with integrins and uPA, which activates the ERK signaling pathway (93). uPAR activation also leads to extravasation and migration of activated T lymphocytes and chemotaxis of polymophonuclear leukocytes (94,95). Interestingly, soluble uPAR is observed in ovarian cancer, multiple myeloma, breast cancer, burn-injuries, and severe sepsis and regulates uPA enzymatic activity and mobilization of hematopoietic stem cells (96-98).

CONCLUSION
The first human Ly-6/uPAR molecule was discovered relatively recently, and various Ly-6/uPAR family proteins have been identified. The studies described in this review have revealed many interesting properties of the human Ly-6/uPAR family of molecules in the context of tissue expression, molecular structure, and function. These molecules share remarkable amino acid homology in terms of conserved cysteine residues, which are crucial for the conformation of the Ly-6/uPAR domain. Some of the Ly-6/uPAR encoding tumor-specific antigens and their recognition by tumor specific cytotoxicity T lymphocytes have opened new avenues for developing effective anticancer immunotherapies. The Ly-6/uPAR members are considered promising candidates for cancer immunotherapy because they are strictly tumor specific and are shared by many kinds of tumors. The Ly-6/uPAR molecules are considered not only cancer vaccine targets but also target antigens for antibody-based immunotherapy. Other Ly-6/uPAR molecules such as SAMP14 and SP-10 are associated with testis-specific expression, and their function in tumorigenesis is unknown. Many aspects of the Ly-6/uPAR family are not fully understood, and future studies in the context of: (i) the relationship between the regulation of human Ly-6/uPAR expression in hematopoiesis and peripheral tissues to cell development and function in vivo and (ii) understanding the mechanisms of tumorigenesis or migration will allow insight into the functional roles of Ly-6/uPAR molecules in vivo.

This research was supported by the Sookmyung Women’s University Research Grants 2010.
==== Refs
1 McKenzie I. F.  Gardiner J.  Cherry M.  Snell G. D.   Lymphocyte antigens: Ly-4, Ly-6, and Ly-7. Transplant Proc.  (1977) 9 667 669 68598 
2 LeClair K. P.  Rabin M.  Nesbitt M. N.  Pravtcheva D.  Ruddle F. H.  Palfree R. G.  Bothwell A.   Murine Ly-6 multigene family is located on chromosome 15. Proc. Natl. Acad. Sci. U.S.A.  (1987) 84 1638 1642 10.1073/pnas.84.6.1638 2882510 
3 Gumley T. P.  McKenzie I. F.  Sandrin M. S.   Tissue expression, structure and function of the murine Ly-6 family of molecules. Immunol. Cell. Biol.  (1995) 73 277 296 10.1038/icb.1995.45 7493764 
4 Li S. H.  Lee R. K.  Lin M. H.  Hwu Y. M.  Lu C. H.  Chen Y. J.  Chen H. C.  Chang W. H.  Chang W. C.   SSLP-1, a secreted Ly-6 protein purified from mouse seminal vesicle fluid. Reproduction  (2006) 132 493 500 10.1530/rep.1.01183 16940290 
5 Havran W. L.  Lancki D. W.  Moldwin R. L.  Dialynas D. P.  Fitch F. W.   Characterization of an anti-Ly-6 monoclonal antibody which defines and activates cytolytic T lymphocytes. J. Immunol.  (1988) 140 1034 1042 3257767 
6 Davies A.  Simmons D. L.  Hale G.  Harrison R. A.  Tighe H.  Lachmann P. J.  Waldmann H.   CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med.  (1989) 170 637 654 10.1084/jem.170.3.637 2475570 
7 Fleming T. J.  O'HUigin C.  Malek T. R.   Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J. Immunol.  (1993) 150 5379 5390 8515066 
8 Meri S.  Morgan B. P.  Davies A.  Daniels R. H.  Olavesen M. G.  Waldmann H.  Lachmann P. J.   Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology  (1990) 71 1 9 1698710 
9 Chang C. P.  Husler T.  Zhao J.  Wiedmer T.  Sims P. J.   Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59. J. Biol. Chem.  (1994) 269 26424 26430 7523406 
10 Treon S. P.  Shima Y.  Grossbard M. L.  Preffer F. I.  Belch A. R.  Pilarski L. M.  Anderson K. C.   Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann. Oncol.  (2000) 11 Suppl 1 107 111 10.1093/annonc/11.suppl_1.S107 10707790 
11 Naderi S.  Hofmann P.  Seiter S.  Tilgen W.  Abken H.  Reinhold U.   CD2-mediated CD59 stimulation in keratinocytes results in secretion of IL-1alpha, IL-6, and GM-CSF: implications for the interaction of keratinocytes with intraepidermal T lymphocytes. Int. J. Mol. Med.  (1999) 3 609 614 10341291 
12 Li B.  Chu X.  Gao M.  Xu Y.   The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol.  (2011) 272 61 70 10.1016/j.cellimm.2011.09.006 22000275 
13 Temerinac S.  Klippel S.  Strunck E.  Roder S.  Lubbert M.  Lange W.  Azemar M.  Meinhardt G.  Schaefer H. E.  Pahl H. L.   Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood  (2000) 95 2569 2576 10753836 
14 Sachs U. J.  Andrei-Selmer C. L.  Maniar A.  Weiss T.  Paddock C.  Orlova V. V.  Choi E. Y.  Newman P. J.  Preissner K. T.  Chavakis T.  Santoso S.   The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J. Biol. Chem.  (2007) 282 23603 23612 10.1074/jbc.M701120200 17580308 
15 Dillon M.  Minear J.  Johnson J.  Lannutti B. J.   Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines. Leuk Res.  (2008) 32 811 819 10.1016/j.leukres.2007.09.018 17980909 
16 Korkmaz B.  Kuhl A.  Bayat B.  Santoso S.  Jenne D. E.   A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. J. Biol. Chem.  (2008) 283 35976 35982 10.1074/jbc.M806754200 18854317 
17 Beigneux A. P.  Davies B. S.  Gin P.  Weinstein M. M.  Farber E.  Qiao X.  Peale F.  Bunting S.  Walzem R. L.  Wong J. S.  Blaner W. S.  Ding Z. M.  Melford K.  Wongsiriroj N.  Shu X.  de Sauvage F.  Ryan R. O.  Fong L. G.  Bensadoun A.  Young S. G.   Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab.  (2007) 5 279 291 10.1016/j.cmet.2007.02.002 17403372 
18 Davies B. S.  Beigneux A. P.  Barnes R. H. 2nd  Tu Y.  Gin P.  Weinstein M. M.  Nobumori C.  Nyren R.  Goldberg I.  Olivecrona G.  Bensadoun A.  Young S. G.  Fong L. G.   GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab.  (2010) 12 42 52 10.1016/j.cmet.2010.04.016 20620994 
19 Quak J. J.  Balm A. J.  van Dongen G. A.  Brakkee J. G.  Scheper R. J.  Snow G. B.  Meijer C. J.   A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am. J. Pathol.  (1990) 136 191 197 2297047 
20 Bartelink H.  Keus R. B.   Progress in radiotherapy by treatment tailoring in head and neck cancer. Curr. Opin. Oncol.  (1991) 3 523 528 10.1097/00001622-199106000-00013 1892922 
21 Nieuwenhuis E. J.  Leemans C. R.  Kummer J. A.  Denkers F.  Snow G. B.  Brakenhoff R. H.   Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction. Lab. Invest.  (2003) 83 1233 1240 10.1097/01.LAB.0000083532.46536.56 12920252 
22 Antica M.  Wu L.  Scollay R.   Stem cell antigen 2 expression in adult and developing mice. Immunol. Lett.  (1997) 55 47 51 10.1016/S0165-2478(96)02682-X 9093881 
23 Noda S.  Kosugi A.  Saitoh S.  Narumiya S.  Hamaoka T.   Protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal through thymic shared antigen-1/stem cell antigen-2. J. Exp. Med.  (1996) 183 2355 2360 10.1084/jem.183.5.2355 8642345 
24 Saitoh S.  Kosugi A.  Noda S.  Yamamoto N.  Ogata M.  Minami Y.  Miyake K.  Hamaoka T.   Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). J. Immunol.  (1995) 155 5574 5581 7499840 
25 Bresson-Mazet C.  Gandrillon O.  Gonin-Giraud S.   Stem cell antigen 2: a new gene involved in the self-renewal of erythroid progenitors. Cell Prolif.  (2008) 41 726 738 10.1111/j.1365-2184.2008.00554.x 18823497 
26 Horie M.  Okutomi K.  Taniguchi Y.  Ohbuchi Y.  Suzuki M.  Takahashi E.   Isolation and characterization of a new member of the human Ly6 gene family (LY6H). Genomics  (1998) 53 365 368 10.1006/geno.1998.5462 9799603 
27 de Nooij-van Dalen A. G.  van Dongen G. A.  Smeets S. J.  Nieuwenhuis E. J.  Stigter-van Walsum M.  Snow G. B.  Brakenhoff R. H.   Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int. J. Cancer  (2003) 103 768 774 10.1002/ijc.10903 12516096 
28 Lee J. W.  Lee Y. S.  Yoo K. H.  Lee K. H.  Park K.  Ahn T.  Ko C.  Park J. H.   LY-6K gene: a novel molecular marker for human breast cancer. Oncol. Rep.  (2006) 16 1211 1214 17089039 
29 Ishikawa N.  Takano A.  Yasui W.  Inai K.  Nishimura H.  Ito H.  Miyagi Y.  Nakayama H.  Fujita M.  Hosokawa M.  Tsuchiya E.  Kohno N.  Nakamura Y.  Daigo Y.   Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res.  (2007) 67 11601 11611 10.1158/0008-5472.CAN-07-3243 18089789 
30 Matsuda R.  Enokida H.  Chiyomaru T.  Kikkawa N.  Sugimoto T.  Kawakami K.  Tatarano S.  Yoshino H.  Toki K.  Uchida Y.  Kawahara K.  Nishiyama K.  Seki N.  Nakagawa M.   LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling. Br. J. Cancer  (2011) 104 376 386 10.1038/sj.bjc.6605990 21063397 
31 Zhang B.  Zhang Z.  Zhang X.  Gao X.  Kernstine K. H.  Zhong L.   Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma. Biomarkers  (2012) 17 372 378 10.3109/1354750X.2012.680609 22515502 
32 Choi S. H.  Kong H. K.  Park S. Y.  Park J. H.   Metastatic effect of LY-6K gene in breast cancer cells. Int. J. Oncol.  (2009) 35 601 607 10.3892/ijo_00000320 19639180 
33 Suda T.  Tsunoda T.  Daigo Y.  Nakamura Y.  Tahara H.   Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci.  (2007) 98 1803 1808 10.1111/j.1349-7006.2007.00603.x 17784873 
34 Yu D. H.  Fan W.  Liu G.  Nguy V.  Chatterton J. E.  Long S.  Ke N.  Meyhack B.  Bruengger A.  Brachat A.  Wong-Staal F.  Li Q. X.   PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway. Exp. Cell Res.  (2006) 312 865 876 10.1016/j.yexcr.2005.12.006 16413018 
35 Egerod K. L.  Holst B.  Petersen P. S.  Hansen J. B.  Mulder J.  Hokfelt T.  Schwartz T. W.   GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol. Endocrinol.  (2007) 21 1685 1698 10.1210/me.2007-0055 17488974 
36 Wurfel J.  Seiter S.  Stassar M.  Claas A.  Klas R.  Rosel M.  Marhaba R.  Savelyeva L.  Schwab M.  Matzku S.  Zoller M.   Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene  (2001) 262 35 41 10.1016/S0378-1119(00)00515-1 11179665 
37 Seiter S.  Stassar M.  Rappl G.  Reinhold U.  Tilgen W.  Zoller M.   Upregulation of C4.4A expression during progression of melanoma. J. Invest. Dermatol.  (2001) 116 344 347 10.1046/j.1523-1747.2001.01230.x 11180013 
38 Fletcher G. C.  Patel S.  Tyson K.  Adam P. J.  Schenker M.  Loader J. A.  Daviet L.  Legrain P.  Parekh R.  Harris A. L.  Terrett J. A.   hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br. J. Cancer  (2003) 88 579 585 10.1038/sj.bjc.6600740 12592373 
39 Paret C.  Hildebrand D.  Weitz J.  Kopp-Schneider A.  Kuhn A.  Beer A.  Hautmann R.  Zoller M.   C4.4A as a candidate marker in the diagnosis of colorectal cancer. Br. J. Cancer  (2007) 97 1146 1156 10.1038/sj.bjc.6604012 17912244 
40 Hansen L. V.  Skov B. G.  Ploug M.  Pappot H.   Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer. Lung Cancer  (2007) 58 260 266 10.1016/j.lungcan.2007.06.025 17706320 
41 Hansen L. V.  Laerum O. D.  Illemann M.  Nielsen B. S.  Ploug M.   Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma. Int. J. Cancer  (2008) 122 734 741 10.1002/ijc.23082 17849475 
42 Oshiro R.  Yamamoto H.  Takahashi H.  Ohtsuka M.  Wu X.  Nishimura J.  Takemasa I.  Mizushima T.  Ikeda M.  Sekimoto M.  Matsuura N.  Doki Y.  Mori M.   C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer. Cancer Sci.  (2012) 103 1155 1164 10.1111/j.1349-7006.2012.02263.x 22404718 
43 Ngora H.  Galli U. M.  Miyazaki K.  Zoller M.   Membrane-bound and exosomal metastasis-associated C4.4A promotes migration by associating with the alpha(6)beta(4) integrin and MT1-MMP. Neoplasia  (2012) 14 95 107 22431918 
44 Zhang Y.  Lang Q.  Li J.  Xie F.  Wan B.  Yu L.   Identification and characterization of human LYPD6, a new member of the Ly-6 superfamily. Mol. Biol. Rep.  (2010) 37 2055 2062 10.1007/s11033-009-9663-7 19653121 
45 Ni J.  Lang Q.  Bai M.  Zhong C.  Chen X.  Wan B.  Yu L.   Cloning and characterization of a human LYPD7, a new member of the Ly-6 superfamily. Mol. Biol. Rep.  (2009) 36 697 703 10.1007/s11033-008-9231-6 18360792 
46 Reiter R. E.  Gu Z.  Watabe T.  Thomas G.  Szigeti K.  Davis E.  Wahl M.  Nisitani S.  Yamashiro J.  Le Beau M. M.  Loda M.  Witte O. N.   Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U.S.A.  (1998) 95 1735 1740 10.1073/pnas.95.4.1735 9465086 
47 Argani P.  Rosty C.  Reiter R. E.  Wilentz R. E.  Murugesan S. R.  Leach S. D.  Ryu B.  Skinner H. G.  Goggins M.  Jaffee E. M.  Yeo C. J.  Cameron J. L.  Kern S. E.  Hruban R. H.   Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res.  (2001) 61 4320 4324 11389052 
48 Amara N.  Palapattu G. S.  Schrage M.  Gu Z.  Thomas G. V.  Dorey F.  Said J.  Reiter R. E.   Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res.  (2001) 61 4660 4665 11406532 
49 Elsamman E. M.  Fukumori T.  Tanimoto S.  Nakanishi R.  Takahashi M.  Toida K.  Kanayama H. O.   The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int.  (2006) 98 668 673 10.1111/j.1464-410X.2006.06350.x 16925770 
50 Sakamoto H.  Yoshimura K.  Saeki N.  Katai H.  Shimoda T.  Matsuno Y.  Saito D.  Sugimura H.  Tanioka F.  Kato S.  Matsukura N.  Matsuda N.  Nakamura T.  Hyodo I.  Nishina T.  Yasui W.  Hirose H.  Hayashi M.  Toshiro E.  Ohnami S.  Sekine A.  Sato Y.  Totsuka H.  Ando M.  Takemura R.  Takahashi Y.  Ohdaira M.  Aoki K.  Honmyo I.  Chiku S.  Aoyagi K.  Sasaki H.  Yanagihara K.  Yoon K. A.  Kook M. C.  Lee Y. S.  Park S. R.  Kim C. G.  Choi I. J.  Yoshida T.  Nakamura Y.  Hirohashi S.   Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet.  (2008) 40 730 740 10.1038/ng.152 18488030 
51 Liu W. K.  Jiang X. Y.  Zhang Z. X.   Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie  (2010) 33 241 245 10.1159/000305098 20502058 
52 Kawaguchi T.  Sho M.  Tojo T.  Yamato I.  Nomi T.  Hotta K.  Hamada K.  Suzaki Y.  Sugiura S.  Kushibe K.  Nakajima Y.  Taniguchi S.   Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn. J. Clin. Oncol.  (2010) 40 319 326 10.1093/jjco/hyp181 20085909 
53 Liu W. K.  Jiang X. Y.  Zhang Z. X.   Expression of PSCA, PIWIL1 and TBX2 and its correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens. Arch. Virol.  (2010) 155 657 663 10.1007/s00705-010-0635-y 20229117 
54 Hao J. Y.  Yang Y. L.  Li S.  Qian X. L.  Liu F. F.  Fu L.   PSCA expression in invasive micropapillary carcinoma of breast. Zhonghua Bing Li Xue Za Zhi  (2011) 40 382 386 21914346 
55 Geiger K. D.  Hendruschk S.  Rieber E. P.  Morgenroth A.  Weigle B.  Juratli T.  Senner V.  Schackert G.  Temme A.   The prostate stem cell antigen represents a novel glioma-associated antigen. Oncol Rep.  (2011) 26 13 21 21503583 
56 Bahrenberg G.  Brauers A.  Joost H. G.  Jakse G.   Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun.  (2000) 275 783 788 10.1006/bbrc.2000.3393 10973799 
57 Ono H.  Hiraoka N.  Lee Y. S.  Woo S. M.  Lee W. J.  Choi I. J.  Saito A.  Yanagihara K.  Kanai Y.  Ohnami S.  Chiwaki F.  Sasaki H.  Sakamoto H.  Yoshida T.  Saeki N.   Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer  (2012) 51 30 41 10.1002/gcc.20928 21936014 
58 Wu X.  Ye Y.  Kiemeney L. A.  Sulem P.  Rafnar T.  Matullo G.  Seminara D.  Yoshida T.  Saeki N.  Andrew A. S.  Dinney C. P.  Czerniak B.  Zhang Z. F.  Kiltie A. E.  Bishop D. T.  Vineis P.  Porru S.  Buntinx F.  Kellen E.  Zeegers M. P.  Kumar R.  Rudnai P.  Gurzau E.  Koppova K.  Mayordomo J. I.  Sanchez M.  Saez B.  Lindblom A.  de Verdier P.  Steineck G.  Mills G. B.  Schned A.  Guarrera S.  Polidoro S.  Chang S. C.  Lin J.  Chang D. W.  Hale K. S.  Majewski T.  Grossman H. B.  Thorlacius S.  Thorsteinsdottir U.  Aben K. K.  Witjes J. A.  Stefansson K.  Amos C. I.  Karagas M. R.  Gu J.   Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet.  (2009) 41 991 995 10.1038/ng.421 19648920 
59 Matsuo K.  Tajima K.  Suzuki T.  Kawase T.  Watanabe M.  Shitara K.  Misawa K.  Ito S.  Sawaki A.  Muro K.  Nakamura T.  Yamao K.  Yamamura Y.  Hamajima N.  Hiraki A.  Tanaka H.   Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int. J. Cancer  (2009) 125 1961 1964 10.1002/ijc.24519 19582881 
60 Kim S. Y.  Yoo J. Y.  Shin A.  Kim Y.  Lee E. S.  Lee Y. S.   Prostate stem cell antigen single nucleotide polymorphisms influence risk of estrogen receptor negative breast cancer in Korean females. Asian Pac. J. Cancer Prev.  (2012) 13 41 48 10.7314/APJCP.2012.13.1.041 22502712 
61 Saffran D. C.  Raitano A. B.  Hubert R. S.  Witte O. N.  Reiter R. E.  Jakobovits A.   Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. U.S.A.  (2001) 98 2658 2663 10.1073/pnas.051624698 11226295 
62 Feng H. C.  Tsao S. W.  Ngan H. Y.  Xue W. C.  Kwan H. S.  Siu M. K.  Liao X. Y.  Wong E.  Cheung A. N.   Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia. Histopathology  (2008) 52 167 174 10.1111/j.1365-2559.2007.02925.x 18184265 
63 Moore M. L.  Teitell M. A.  Kim Y.  Watabe T.  Reiter R. E.  Witte O. N.  Dubey P.   Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate  (2008) 68 139 151 10.1002/pros.20686 18044730 
64 Marra E.  Uva P.  Viti V.  Simonelli V.  Dogliotti E.  De Rinaldis E.  Lahm A.  La Monica N.  Nicosia A.  Ciliberto G.  Palombo F.   Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer  (2010) 10 129 10.1186/1471-2407-10-129 20374648 
65 Shetty J.  Wolkowicz M. J.  Digilio L. C.  Klotz K. L.  Jayes F. L.  Diekman A. B.  Westbrook V. A.  Farris E. M.  Hao Z.  Coonrod S. A.  Flickinger C. J.  Herr J. C.   SAMP14, a novel, acrosomal membrane-associated, glycosylphosphatidylinositol-anchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm-egg interaction. J. Biol. Chem.  (2003) 278 30506 30515 10.1074/jbc.M301713200 12788941 
66 Adermann K.  Wattler F.  Wattler S.  Heine G.  Meyer M.  Forssmann W. G.  Nehls M.   Structural and phylogenetic characterization of human SLURP-1, the first secreted mammalian member of the Ly-6/uPAR protein superfamily. Protein. Sci.  (1999) 8 810 819 10.1110/ps.8.4.810 10211827 
67 Fischer J.  Bouadjar B.  Heilig R.  Huber M.  Lefevre C.  Jobard F.  Macari F.  Bakija-Konsuo A.  Ait-Belkacem F.  Weissenbach J.  Lathrop M.  Hohl D.  Prud J. F.   Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum. Mol. Genet  (2001) 10 875 880 10.1093/hmg/10.8.875 11285253 
68 Tsuji H.  Okamoto K.  Matsuzaka Y.  Iizuka H.  Tamiya G.  Inoko H.   SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris. Genomics  (2003) 81 26 33 10.1016/S0888-7543(02)00025-3 12573258 
69 Arredondo J.  Chernyavsky A. I.  Webber R. J.  Grando S. A.   Biological effects of SLURP-1 on human keratinocytes. J. Invest. Dermatol.  (2005) 125 1236 1241 10.1111/j.0022-202X.2005.23973.x 16354194 
70 Pettersson A.  Nordlander S.  Nylund G.  Khorram-Manesh A.  Nordgren S.  Delbro D. S.   Expression of the endogenous, nicotinic acetylcholine receptor ligand, SLURP-1, in human colon cancer. Auton Autacoid. Pharmacol.  (2008) 28 109 116 10.1111/j.1474-8673.2008.00424.x 18764860 
71 Phan T. C.  Ooi J.  Goonewardene M. S.   A novel molecule, SLURP-1, enhances the survival of periodontal ligament fibroblasts. J. Periodontal. Res.  (2010) 45 331 336 10.1111/j.1600-0765.2009.01240.x 20337899 
72 Tjiu J. W.  Lin P. J.  Wu W. H.  Cheng Y. P.  Chiu H. C.  Thong H. Y.  Chiang B. L.  Yang W. S.  Jee S. H.   SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda. Br. J. Dermatol.  (2011) 164 47 53 10.1111/j.1365-2133.2010.10059.x 20854438 
73 Arredondo J.  Chernyavsky A. I.  Jolkovsky D. L.  Webber R. J.  Grando S. A.   SLURP-2: A novel cholinergic signaling peptide in human mucocutaneous epithelium. J. Cell. Physiol.  (2006) 208 238 245 10.1002/jcp.20661 16575903 
74 Moriwaki Y.  Yoshikawa K.  Fukuda H.  Fujii Y. X.  Misawa H.  Kawashima K.   Immune system expression of SLURP-1 and SLURP-2, two endogenous nicotinic acetylcholine receptor ligands. Life Sci.  (2007) 80 2365 2368 10.1016/j.lfs.2006.12.028 17286989 
75 Anderson D. J.  Johnson P. M.  Alexander N. J.  Jones W. R.  Griffin P. D.   Monoclonal antibodies to human trophoblast and sperm antigens: report of two WHO-sponsored workshops, June 30, 1986-Toronto, Canada. J. Reprod. Immunol.  (1987) 10 231 257 10.1016/0165-0378(87)90089-1 3585867 
76 Herr J. C.  Flickinger C. J.  Homyk M.  Klotz K.  John E.   Biochemical and morphological characterization of the intra-acrosomal antigen SP-10 from human sperm. Biol. Reprod.  (1990) 42 181 193 10.1095/biolreprod42.1.181 2310816 
77 Kurth B. E.  Klotz K.  Flickinger C. J.  Herr J. C.   Localization of sperm antigen SP-10 during the six stages of the cycle of the seminiferous epithelium in man. Biol. Reprod.  (1991) 44 814 821 10.1095/biolreprod44.5.814 1868140 
78 Vassalli J. D.  Baccino D.  Belin D.   A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol.  (1985) 100 86 92 10.1083/jcb.100.1.86 3880760 
79 Mondino A.  Resnati M.  Blasi F.   Structure and function of the urokinase receptor. Thromb Haemost  (1999) 82 Supp 1 19 22 10695480 
80 Schlechte W.  Murano G.  Boyd D.   Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res.  (1989) 49 6064 6069 2551498 
81 Del Vecchio S.  Stoppelli M. P.  Carriero M. V.  Fonti R.  Massa O.  Li P. Y.  Botti G.  Cerra M.  D G.  Esposito G.  Salvatore M.   Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res.  (1993) 53 3198 3206 7686450 
82 de Vries T. J.  Quax P. H.  Denijn M.  Verrijp K. N.  Verheijen J. H.  Verspaget H. W.  Weidle U. H.  Ruiter D. J.  van Muijen G. N.   Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol . (1994) 144 70 81 8291613 
83 Mohanam S.  Sawaya R. E.  Yamamoto M.  Bruner J. M.  Nicholson G. L.  Rao J. S.   Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. J. Neurooncol.  (1994) 22 153 160 10.1007/BF01052890 7745467 
84 Pedersen H.  Brunner N.  Francis D.  Osterlind K.  Ronne E.  Hansen H. H.  Dano K.  Grondahl- Hansen J.   Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res.  (1994) 54 4671 4675 8062262 
85 Wagner S. N.  Atkinson M. J.  Thanner S.  Wagner C.  Schmitt M.  Wilhelm O.  Rotter M.  Hofler H.   Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am. J. Pathol.  (1995) 147 183 192 7604879 
86 Morita Y.  Hayashi Y.  Wang Y.  Kanamaru T.  Suzuki S.  Kawasaki K.  Ohta K.  Yamamoto M.  Saitoh Y.  Itoh H.  Doe W. F.   Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology  (1997) 25 856 861 10.1002/hep.510250412 9096588 
87 Yonemura Y.  Nojima N.  Kawamura T.  Ajisaka H.  Taniguchi K.  Fujimura T.  Fujita H.  Bandou E.  Fushida S.  Endou Y.  Obata T.  Sasaki T.   Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma. Oncol. Rep.  (1997) 4 1229 1234 21590227 
88 Sier C. F.  Stephens R.  Bizik J.  Mariani A.  Bassan M.  Pedersen N.  Frigerio L.  Ferrari A.  Dano K.  Brunner N.  Blasi F.   The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res.  (1998) 58 1843 1849 9581823 
89 Schmidt M.  Hoppe F.   Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients. Acta. Otolaryngol.  (1999) 119 949 953 10.1080/00016489950180342 10728940 
90 Nozaki S.  Endo Y.  Nakahara H.  Yoshizawa K.  Hashiba Y.  Kawashiri S.  Tanaka A.  Nakagawa K.  Matsuoka Y.  Kogo M.  Yamamoto E.   Inhibition of invasion and metastasis in oral cancer by targeting urokinase- type plasminogen activator receptor. Oral Oncol.  (2005) 41 971 977 10.1016/j.oraloncology.2005.05.013 16129656 
91 Wang J.  Guo F.  Wei H.  Dong J.  Wu J.   Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma. Br. J. Oral. Maxillofac. Surg.  (2006) 44 515 519 10.1016/j.bjoms.2005.10.009 16356605 
92 Hildenbrand R.  Niedergethmann M.  Marx A.  Belharazem D.  Allgayer H.  Schleger C.  Strobel P.   Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am. J. Pathol.  (2009) 174 2246 2253 10.2353/ajpath.2009.080785 19435784 
93 Ossowski L.  Aguirre-Ghiso J. A.   Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol.  (2000) 12 613 620 10.1016/S0955-0674(00)00140-X 10978898 
94 Nykjaer A.  Moller B.  Todd R. F. 3rd  Christensen T.  Andreasen P. A.  Gliemann J.  Petersen C. M.   Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol.  (1994) 152 505 516 8283034 
95 Gyetko M. R.  Sitrin R. G.  Fuller J. A.  Todd R. F. 3rd  Petty H.  Standiford T. J.   Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J. Leukoc. Biol.  (1995) 58 533 538 7595054 
96 Pedersen N.  Schmitt M.  Ronne E.  Nicoletti M. I.  Hoyer-Hansen G.  Conese M.  Giavazzi R.  Dano K.  Kuhn W.  Janicke F.  Blasi F.   A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J. Clin. Invest.  (1993) 92 2160 2167 10.1172/JCI116817 8227331 
97 Rigolin G. M.  Tieghi A.  Ciccone M.  Bragotti L. Z.  Cavazzini F.  Della Porta M.  Castagnari B.  Carroccia R.  Guerra G.  Cuneo A.  Castoldi G.   Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br. J. Haematol.  (2003) 120 953 959 10.1046/j.1365-2141.2003.04176.x 12648064 
98 Nijziel M. R.  Van Oerle R.  Hellenbrand D.  Van Pampus E. C.  Hillen H. F.  Hamulyak K.   The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J. Thromb. Haemost.  (2003) 1 982 986 10.1046/j.1538-7836.2003.00207.x 12871365 
99 Saitou N.  Nei M.   The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol.  (1987) 4 406 425 3447015 
100 Whelan S.  Goldman N.   A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach. Mol. Biol. Evol.  (2001) 18 691 699 10.1093/oxfordjournals.molbev.a003851 11319253
